

- [0620] 23. Frey, G. et al. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci U S A 105, 3739-3744 (2008).
- [0621] 24. Chen, J. et al. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. Journal of virology 88, 1249-1258, doi:10.1128/JVI.02664-13 (2014).
- [0622] 25. Alam, S. M. et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 106, 20234-20239, doi: 0908713106 [pii] 10.1073/pnas.0908713106 (2009).
- [0623] 26. Dimitrov, A. S., Rawat, S. S., Jiang, S. & Blumenthal, R. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion. Biochemistry 42, 14150-14158 (2003).
- [0624] 27. Munoz-Barroso, I., Salzwedel, K., Hunter, E. & Blumenthal, R. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. Journal of virology 73, 6089-6092 (1999).
- [0625] 28. Salzwedel, K., West, J. T. & Hunter, E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. Journal of virology 73, 2469-2480 (1999).
- [0626] 29. Muster, T. et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67, 6642-6647 (1993).
- [0627] 30. Stiegler, G. et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17, 1757-1765 (2001).
- [0628] 31. Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406-412, doi: 10.1038/nature11544 (2012).
- [0629] 32. Trkola, A. et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nature medicine 11, 615-622, doi:10.1038/nm1244 (2005).
- [0630] 33. Frey, G. et al. Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nature structural & molecular biology 17, 1486-1491, doi:10.1038/nsmb.1950 (2010).
- [0631] 34. Weissenbacher, E. R. et al. A comparison of dequalinium chloride vaginal tablets (Fluomizin(R)) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecologic and obstetric investigation 73, 8-15, doi:10.1159/000332398 (2012).
- [0632] 35. Nkolola, J. P. et al. Breadth of neutralizing antibodies elicited by stable, homogeneous Glade A and Glade C HIV-1 gp140 envelope trimers in guinea pigs. Journal of virology 84, 3270-3279, doi:10.1128/JVI.02252-09 (2010).
- [0633] 36. Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79, 10108-10125 (2005).
- [0634] 37. Mascola, J. R. et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79, 10103-10107 (2005).
- [0635] 38. Robinson, W. E., Jr. et al. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol 64, 5301-5305 (1990).
- [0636] 39. Clackson, T. & Wells, J. A. A hot spot of binding energy in a hormone-receptor interface. Science 267, 383-386, doi:10.1126/science.7529940 (1995).
- [0637] 40. Liao, Y., Zhang, S. M., Neo, T. L. & Tam, J. P. Tryptophan-dependent membrane interaction and heteromerization with the internal fusion peptide by the membrane proximal external region of SARS-CoV spike protein. Biochemistry 54, 1819-1830, doi:10.1021/bi501352u (2015).
- [0638] 41. Song, L. et al. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc Natl Acad Sci U S A 106, 9057-9062, doi:10.1073/pnas.0901474106 (2009).
- [0639] 42. Fu, Q. et al. Structure of the membrane proximal external region of HIV-1 envelope glycoprotein. Proc Natl Acad Sci USA 115, E8892-E8899, doi:10.1073/pnas.1807259115 (2018).
- [0640] 43. Pace, C. N. et al. Contribution of hydrophobic interactions to protein stability. J Mol Biol 408, 514-528, doi:10.1016/j.jmb.2011.02.053 (2011).
- [0641] 44. Bryson, S., Julien, J. P., Hynes, R. C. & Pai, E. F. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. J Virol 83, 11862-11875, doi:10.1128/JVI.01604-09 (2009).
- [0642] 45. Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. Journal of biomolecular NMR 6, 277-293 (1995).
- [0643] 46. Schwieters, C. D., Kuszewski, J. J., Tjandra, N. & Clore, G. M. The Xplor-NIH NMR molecular structure determination package. Journal of magnetic resonance 160, 65-73 (2003).
1. A compound of Formula (I):
- FORMULA (I)
-
- and pharmaceutically acceptable salts thereof,
wherein:
n is an integer from 3 to 14;
R and R' are independently selected from the group
consisting of:
(i) Formula (II):
- FORMULA (II)
-